pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,568 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1056Endpoints798BioPharma Dive307BioSpace231Fierce Biotech219onclive165raps82globenewswire health
therapy area
allOncology6233Rare Disease1510Cardiology1127Hematology1078Immunology1048Vaccines945Pulmonology
  • FDA acting director of cell and gene therapies Vijay Kumar to depart his post
    Vijay Kumar, who has been serving as the acting director of the Center for Biologics Evaluation and Research (CBER) Office of Therapeutic Products, announced he will leave his position. In an inte…
    Endpoints · 1mo agoNeutral↗ source
  • Nominations Open for 2026 Endpoints 11 Biotech Awards
    Nominations for the 2026 Endpoints 11 awards are now being accepted, with submissions due by July 15. The awards target private biotech startups that have differentiated science, strong leadership…
    Endpoints · 1mo agoNeutral↗ source
← prev
page 41 of 63
next →
73
fda recalls51
fda medwatch46
fda press28
923
Psychiatry & CNS745
Ophthalmology451
Pain418
Endocrinology & Metabolism395
Infectious Disease379
NEJM retracts pivotal data for Amgen's Tavneos, adding new hurdle for the autoimmune drug
The New England Journal of Medicine has withdrawn the pivotal data that supported Amgen’s autoimmune therapy Tavneos. The retraction was requested by two academic authors who raised concerns about…
Endpoints · 1mo agoNegative↗ source
  • Zymeworks CEO says $1 billion Theravance acquisition offers strong value despite recent setbacks
    Zymeworks chief executive Kenneth Galbraith explained why the company believes its near-$1 billion purchase of Theravance makes strategic sense. He noted that Theravance has faced operational diff…
    Endpoints · 1mo agoDealPositive↗ source
  • Evommune's lead drug fails in chronic hives trial, shares tumble over 30%
    Evommune reported its first major trial readout since going public last year, focusing on its lead candidate for chronic spontaneous urticaria, a condition where patients experience recurring hives…
    Endpoints · 1mo agoNegative readoutNegative↗ source
  • Talawar Therapeutics merges with JATT II Acquisition to list on Nasdaq as AstraZeneca reports Phase 3 success in pediatric bone disease
    Talawar Therapeutics announced a combination with blank‑check company JATT II Acquisition Corp, a deal that will place Talawar on the Nasdaq exchange. The SPAC transaction gives Talawar public‑mar…
    Endpoints · 1mo agoDealPositive↗ source
  • Chinese partnerships are becoming the pharma industry's new tax inversion strategy
    The article notes that a decade after the wave of U.S. tax inversions, the pharmaceutical sector is now seeing a similar pattern with deals involving Chinese entities. Analysts argue that these tra…
    Endpoints · 1mo agoDealNeutral↗ source
  • BioCryst to shut internal drug discovery and close Alabama research site
    BioCryst Pharmaceuticals announced it is winding down its internal drug discovery efforts. The company said it will seek future programs through external collaborations rather than in‑house resear…
    Endpoints · 1mo agoNegative↗ source
  • J&J EVP John Reed Discusses R&D Model, Oncology Deals and Pipeline Growth Potential
    John Reed, executive vice president of Innovative Medicine at Johnson & Johnson, brings more than a decade of experience overseeing drug pipelines at three of the world’s largest pharmaceutical com…
    Endpoints · 1mo agoNeutral↗ source
  • Over 200 biopharma investors urge EU governments to strengthen Europe's life-science sector
    More than 200 biopharma investors and companies have signed an open letter addressed to EU member states, calling for action to improve Europe's life‑science sector. The signatories argue that Eur…
    Endpoints · 1mo agoRegulatoryNeutral↗ source
  • Ipsen to buy blood cancer company Kartos Therapeutics for $450M upfront
    Ipsen is earmarking up to $1.75 billion to take Kartos Therapeutics and its MDM2 protein-targeting drug candidate that it in-licensed from Amgen back in 2016. Ipsen will pay $450 million upfront ...
    Endpoints · 1mo ago↗ source
  • De-Risking a Rare Disease Launch Starts with Precision
    Why traditional models fall short in rare disease commercialization—and what works instead.
    Fierce Biotech · 2mo ago↗ source
  • Biopharma’s LGBTQ+ leaders; Novo Nordisk hacked?; and more
    Welcome back to another edition of Endpoints Weekly! The summer solstice arrives this weekend — the northern hemisphere will reach its maximum tilt toward the sun at 4:24 a.m. Eastern time on Sunda…
    Endpoints · 2mo ago↗ source
  • Endpoints News History: 10 Years, Bootstrap to FT
    Ten years of Endpoints News: no investors, a 50/50 split, profitable from day one. Co-founders Arsalan Arif and John Carroll on how the partnership held.
    Endpoints · 2mo ago↗ source
  • US government launches probe into Germany's plan to pay less for drugs
    Amid Germany's ongoing review of its healthcare spending, the US government has started a trade investigation into the European country's drug pricing system. The investigation, under Section 301 o…
    Endpoints · 2mo ago↗ source
  • FDA vaccine advisors unanimously support Moderna's flu shot
    Every member of a vaccine advisory panel for the FDA voted in favor of Moderna’s flu vaccine, after the product faced roadblocks from previous agency leadership. The Vaccines and Related Biological…
    Endpoints · 2mo ago↗ source
  • Treasury weighs screening investments in China biotech
    Officials at the Treasury Department are looking at potential restrictions on US investments in China biotech, according to multiple sources familiar with the discussions. At least two sources told…
    Endpoints · 2mo ago↗ source
  • Novo Nordisk expands in China and Czech; Cellares boosts Series D by $50M
    Plus more from Eisai and Siegfried. 🧱 Novo Nordisk's expansions: Novo Nordisk has invested around $380 million to expand its manufacturing facility in Bohumil, Central Bohemia, in the Czech Republ…
    Endpoints · 2mo ago↗ source
  • IRA's Medicare out-of-pocket cap increased access to drugs, study finds
    Medication usage, particularly for the most expensive drugs, increased significantly shortly after the Medicare annual out-of-pocket cost cap took effect in January 2025, a study published in JAMA…
    Endpoints · 2mo ago↗ source
  • Prepping for peptides
    It wasn’t too many years ago when we were busy theorizing about the market opportunity for GLP-1 weight loss drugs. Now, the big question is the moneymaking potential for other peptides that might…
    Endpoints · 2mo ago↗ source
  • Pfizer CFO to depart; GSK wins approval for UTI drug
    Plus news about Apellis Pharmaceuticals, Servier, TORL BioTherapeutics, Verastem, Corcept Therapeutics, Legend Biotech, COUR Pharmaceuticals, cAMPfield Therapeutics and LabGenius Therapeutics. 👋 P…
    Endpoints · 2mo ago↗ source
  • RA, Forbion and Sanofi Ventures appear to back new eye drug from Korea
    The trend continues in which big-name venture investors band together to back new companies with an experimental medicine developed by another biotech. RA Capital and Forbion — partners on a couple…
    Endpoints · 2mo ago↗ source
  • Novocure’s electric fields therapy fails key glioblastoma study
    Novocure reported Thursday morning that its electric fields device combined with chemoradiation failed to extend glioblastoma patients' lives in a Phase 3 study, dampening the company's hopes of ex…
    Endpoints · 2mo ago↗ source
  • Innoviva revives Lyndra's long-acting oral drug platform
    A healthcare asset and royalties holding company is bringing a long-acting oral medicine approach back to life, resurrecting a drug delivery platform that had accumulated more than $380 million in…
    Endpoints · 2mo ago↗ source
  • Moderna adds commercial chief, expands Stephen Hoge's role; Reunion Neuroscience CEO departs
    → In preparation for potential new product launches, Moderna has selected Ester Banque as chief commercial officer and expanded the role of president Stephen Hoge. Banque was head of US operations…
    Endpoints · 2mo ago↗ source